Skip to Content
  • Expertology

    I’ve been thinking about “right to try” laws, the ones that are trying to open up access to not-yet-approved drugs for patients who wish to ta… Read More
  • AstraZeneca’s Nasty Surprise

    Something got severely screwed up here. That’s the only conclusion I can draw after seeing AstraZeneca get a Complete Response Letter (CRL) from the FDA f… Read More
  • Sarepta’s Day at the FDA

    I last wrote about Sarepta and eteplirsen, their proposed therapy for Duchenne muscular dystrophy, here. They’re in front of an FDA advisory committee to… Read More
  • Don’t Try to Leave

    The proposed Pfizer-Allergan deal has entered a new stage, and how. You’ll recall that Pfizer has been shopping for years for a way to change its US tax s… Read More
  • Update on Catalyst Pharmaceuticals

    I wanted to update readers on Catalyst Pharmaceuticals, whom I first wrote about here. They’re the ones who have been planning 3,4-diaminopyridine (DAP),… Read More
Page 4 of 23« First...23456...1020...Last »